C
58.18
-1.43 (-2.40%)
| Previous Close | 59.61 |
| Open | 59.53 |
| Volume | 83,537 |
| Avg. Volume (3M) | 678,226 |
| Market Cap | 5,238,271,488 |
| Price / Sales | 4.13 |
| Price / Book | 6.39 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 |
| Operating Margin (TTM) | -29,525.22% |
| Diluted EPS (TTM) | -3.70 |
| Quarterly Revenue Growth (YOY) | -59.60% |
| Total Debt/Equity (MRQ) | 6.31% |
| Current Ratio (MRQ) | 16.39 |
| Operating Cash Flow (TTM) | -199.81 M |
| Levered Free Cash Flow (TTM) | -115.20 M |
| Return on Assets (TTM) | -24.29% |
| Return on Equity (TTM) | -40.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.30 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.80% |
| % Held by Institutions | 94.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Cantor Fitzgerald, 54.69%) | Buy |
| Median | 80.50 (38.36%) | |
| Low | 74.00 (Citigroup, 27.19%) | Buy |
| Average | 81.25 (39.65%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 55.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 14 Nov 2024 | 74.00 (27.19%) | Buy | 59.66 |
| HC Wainwright & Co. | 13 Nov 2024 | 81.00 (39.22%) | Buy | 58.92 |
| JMP Securities | 27 Sep 2024 | 80.00 (37.50%) | Buy | 50.75 |
| Cantor Fitzgerald | 16 Sep 2024 | 90.00 (54.69%) | Buy | 53.94 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KNIGHT JEFF E. | - | 56.06 | -501 | -28,086 |
| Aggregate Net Quantity | -501 | |||
| Aggregate Net Value ($) | -28,086 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 56.06 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KNIGHT JEFF E. | Officer | 22 Nov 2024 | Automatic sell (-) | 501 | 56.06 | 28,086 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |